Literature DB >> 20807524

Effect of non-genetic factors on paraoxonase 1 activity in patients undergoing hemodialysis.

Marija Grdić Rajković1, Lada Rumora, Dubravka Juretić, Tihana Zanić Grubisić, Zlata Flegar-Mestrić, Nada Vrkić, Zeljko Sinjeri, Karmela Barisić.   

Abstract

OBJECTIVES: Hemodialyzed patients have lower paraoxonase 1 (PON1) activity. Higher mortality risk from cardiovascular disease observed in these patients could be due to the low antiathetrogenic activity of PON1. Understanding the mechanism that causes lower PON1 activity could provide the possibility for modulation of enzyme activity in purpose of preventing and/or decreasing development of atherosclerosis. DESIGN AND METHODS: 87 healthy individuals and 71 hemodialyzed patients were enrolled in this study.
RESULTS: Hemodialyzed patients had reduced PON1 paraoxonase and arylesterase activity, concentrations of HDL, HDL(3) and HDL(2) and concentrations of free thiol groups. Distribution of HDL subfractions and distribution of PON1 phenotypes as well as concentrations of MDA were not different between two study groups. In the in vitro experiment high concentrations of urea, creatinine, uric acid and addition of patient's sera ultrafiltrate did not significantly affect PON1 paraoxonase activity.
CONCLUSION: Decreased HDL concentration as well as lower PON1 concentration (shown indirectly by the enzyme arylesterase activity) might contribute, at least partly, to the reduced PON1 activity observed in hemodialyzed patients. Decreased concentration of free thiol groups in sera suggest that free thiol group (Cys284) in PON1 might also be oxidized, which can affect PON1 activity.
Copyright © 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807524     DOI: 10.1016/j.clinbiochem.2010.08.024

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

1.  Paraoxonase-1 Regulation of Renal Inflammation and Fibrosis in Chronic Kidney Disease.

Authors:  Fatimah K Khalaf; Chrysan J Mohammed; Prabhatchandra Dube; Jacob A Connolly; Apurva Lad; Usman M Ashraf; Joshua D Breidenbach; Robin C Su; Andrew L Kleinhenz; Deepak Malhotra; Amira F Gohara; Steven T Haller; David J Kennedy
Journal:  Antioxidants (Basel)       Date:  2022-04-30

2.  Paraoxonase 1 in chronic kidney failure.

Authors:  Alejandro Gugliucci; Kazuhiko Kotani; Satoshi Kimura
Journal:  J Lipids       Date:  2012-03-07

3.  Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease.

Authors:  David J Kennedy; W H Wilson Tang; Yiying Fan; Yuping Wu; Shirley Mann; Michael Pepoy; Stanley L Hazen
Journal:  J Am Heart Assoc       Date:  2013-04-04       Impact factor: 5.501

4.  Paraoxonase 1 activity and phenotype distribution in premenopausal and postmenopausal women.

Authors:  Dražan Butorac; Ivana Celap; Sanja Kačkov; Vera Robić; Tomislav Miletić; Zlata Flegar Meštrić; Andrea Hulina; Krunoslav Kuna; Tihana Žanić Grubišić; Marija Grdić Rajković
Journal:  Biochem Med (Zagreb)       Date:  2014-06-15       Impact factor: 2.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.